XML 68 R52.htm IDEA: XBRL DOCUMENT
v3.8.0.1

License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail) - USD ($) $ in Thousands | 12 Months Ended
--- | ---
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015
License And Collaboration Agreements [Line Items] |  |  |
License, collaboration and other revenue | $ 210,965 | $ 60,382 | $ 165,604
Eli Lilly and Company [Member] | NKTR-358 [Member] |  |  |
License And Collaboration Agreements [Line Items] |  |  |
License, collaboration and other revenue | 130,087 |  |
Ophthotech Corporation [Member] | Fovista [Member] |  |  |
License And Collaboration Agreements [Line Items] |  |  |
License, collaboration and other revenue | 19,123 | 1,408 | 1,398
Bayer Healthcare LLC [Member] | BAY41-6551 (Amikacin Inhale) [Member] |  |  |
License And Collaboration Agreements [Line Items] |  |  |
License, collaboration and other revenue | 17,931 | 1,429 | 1,919
Baxalta Incorporated/Shire [Member] | ADYNOVATE [Member] |  |  |
License And Collaboration Agreements [Line Items] |  |  |
License, collaboration and other revenue | 11,443 | 650 | 10,694
MAP Pharmaceuticals, Inc. / Allergan [Member] | SEMPRANA [Member] |  |  |
License And Collaboration Agreements [Line Items] |  |  |
License, collaboration and other revenue | 11,000 |  |
Amgen, Inc. [Member] | Neulasta [Member] |  |  |
License And Collaboration Agreements [Line Items] |  |  |
License, collaboration and other revenue | 5,000 | 5,000 | 5,000
AstraZeneca AB [Member] | MOVANTIK and MOVANTIK fixed-dose combination program [Member] |  |  |
License And Collaboration Agreements [Line Items] |  |  |
License, collaboration and other revenue | 4,600 | 33,000 | 130,000
Daiichi Sankyo Europe GmbH [Member] | ONZEALDTM (NKTR-102) [Member] |  |  |
License And Collaboration Agreements [Line Items] |  |  |
License, collaboration and other revenue | 3,811 | 3,690 |
Roche [Member] | PEGASYS and MIRCERA [Member] |  |  |
License And Collaboration Agreements [Line Items] |  |  |
License, collaboration and other revenue |  | 7,685 | 12,816
Other [Member] |  |  |
License And Collaboration Agreements [Line Items] |  |  |
License, collaboration and other revenue | $ 7,970 | $ 7,520 | $ 3,777

X
- Definition License and collaboration agreements. + References No definition available. + Details
Name: | nktr_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix: | nktr_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees. + References No definition available. + Details
Name: | nktr_LicenseCollaborationOtherRevenue
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_OphthotechCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_FovistaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_BayerHealthcareLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrShirePLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_ADYNOVATEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_MAPPharmaceuticalsIncOrAllerganMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_SempranaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_AmgenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_NeulastaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_AstraZenecaAbMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKAndMOVANTIKFixedDoseCombinationProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_DaiichiSankyoEuropeGmbHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_ONZEALDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_RocheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_PEGASYSAndMIRCERAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_OtherPartnerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |